{
    "clinical_study": {
        "@rank": "72074", 
        "arm_group": {
            "arm_group_label": "Subjects with advanced Parkinson's disease", 
            "description": "Subjects with advanced Parkinson's Disease implanted with Medtronic DBS system"
        }, 
        "brief_summary": {
            "textblock": "To evaluate DBS device settings and match with the features of the DBS care management\n      software."
        }, 
        "brief_title": "Retrospective, Non-significant Risk, Deep Brain Stimulation (DBS) Care Management Software Study", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Parkinson's Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient with Medtronic Deep Brain Stimulation therapy for idiopathic levodopa\n             responsive Parkinson's Disease\n\n          -  Patient who has had lead placement in the Subthalamic nucleus\n\n          -  Patient with pre-op MRI available\n\n          -  Patient with post-op CT scan available showing placement of the lead\n\n          -  Patient who has documented improvement of at least 35% on UPDRS III scores from\n             baseline preoperative off medication state compared to post DBS implant stimulation\n             on/medications off\n\n        Exclusion Criteria:\n\n          -  Patient who has had clinically significant persistent stimulation related adverse\n             effects\n\n          -  Patient who has evidence of lead migration without lead revision\n\n          -  Patient with other brain malformations that would make it difficult to process images\n             (ablative surgery in the basal ganglia, resective surgery, brain tumor)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Parkinson's disease patients who have been implanted with the DBS system"
            }
        }, 
        "enrollment": {
            "#text": "23", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01750242", 
            "org_study_id": "1669"
        }, 
        "intervention": {
            "arm_group_label": "Subjects with advanced Parkinson's disease", 
            "description": "Patients implanted with the Medtronic DBS system due to their advanced Parkinson's disease", 
            "intervention_name": "Medtronic DBS system", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "La Jolla", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92037"
                    }, 
                    "name": "Scripps Clinic, Division of Neurology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66160"
                    }, 
                    "name": "Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Optivise Map Concordance Study", 
        "overall_official": [
            {
                "affiliation": "Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center", 
                "last_name": "Rajesh Pahwa, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Scripps Clinic Division of Neurology", 
                "last_name": "Melissa Houser, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "To characterize the percentage of leads where the target map and the clinically-derived activation map overlap", 
            "safety_issue": "No", 
            "time_frame": "18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01750242"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change in UPDRS III scores from baseline to follow-up.", 
            "safety_issue": "No", 
            "time_frame": "18 months"
        }, 
        "source": "MedtronicNeuro", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MedtronicNeuro", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}